Skip to main content
SpringerLink
Log in

Lymph Node

  • Chapter
  • First Online:
Handbook of Practical Immunohistochemistry

  • 1948 Accesses

Abstract

This chapter provides information about immunohistochemical (IHC) studies used in diagnosing hematolymphoid neoplasms in an up-to-date and easy-to-use format for the busy pathologists. It lists the most useful IHC markers of lymphoid and histiocytic/dendritic neoplasms based on new WHO classification of tumor of hematopoietic and lymphoid tissue (2017). The third edition of this chapter is to add the new diseases and new antibodies described in the recent WHO classification. The genetic information in mature B-cell lymphomas, T- and NK-cell lymphomas, and classical Hodgkin lymphomas is added in Tables 31.9, 31.10, and 31.11, which includes most abnormalities of cytogenetics and genes in these lymphomas and the clinic impact of these abnormalities. Most recent general information about IHC markers used in hematopoietic neoplasms is listed in Table 31.1. When a lymph node biopsy is suspected to have a hematopoietic neoplasm, the frequently used markers are presented in Table 31.2. Tables 31.3 to 31.7 illustrate the common and new IHC markers used for the differential diagnoses of mature B-cell lymphomas, mature T-cell lymphomas, and lymphoid neoplasms with blastic morphology. IHC markers helpful in lymphomas may also be expressed in non-hematopoietic neoplasms; these are explained in Table 31.8. Other tables focus on IHC markers used for specific lymphoid or histiocytic/dendritic neoplasms according to new WHO classification. We hope that this chapter will be useful in diagnosing and in differentiating lymphomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Lester SC. Special studies. In: Manual of surgical pathology. 2nd ed. Philadelphia: Elsevier; 2006. p. 72–170.

    Google Scholar 

  2. Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med. 2008;132(3):441–61.

    Article  PubMed  Google Scholar 

  3. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885–92.

    Article  CAS  PubMed  Google Scholar 

  4. Stamenkovic I, Asheim HC, Deggerdal A, Blomhoff HK, Smeland EB, Funderudt S. The B cell antigen CD75 is a cell surface sialytransferase. J Exp Med. 1990;172(2):641–3.

    Article  CAS  PubMed  Google Scholar 

  5. Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F, Nandurkar H. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. Leuk Lymphoma. 2009;50(10):1666–75.

    Article  CAS  PubMed  Google Scholar 

  6. Tandon B, Peterson L, Gao J, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24(11):1433–43.

    Article  CAS  PubMed  Google Scholar 

  7. Erdfelder F, Hertweck M, Filipovich A, Uhrmacher S, Kreuzer KA. High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol Rep. 2010;2(1):e3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Farren TW, Giustiniani J, Liu FT, et al. Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood. 2011;118(8):2174–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33(9):1212–6.

    Article  CAS  PubMed  Google Scholar 

  10. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms. Am J Clin Pathol. 2010;134(5):726–33.

    Article  CAS  PubMed  Google Scholar 

  11. El Desoukey NA, Afify RA, Amin DG, Mohammed RF. CD200 expression in B-cell chronic lymphoproliferative disorders. J Investig Med. 2012;60(1):56–61.

    Article  PubMed  Google Scholar 

  12. Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137(1):93–100.

    Article  PubMed  Google Scholar 

  13. Kretz-Rommel A, Bowdish KS. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opin Biol Ther. 2008;8(1):5–15.

    Article  CAS  PubMed  Google Scholar 

  14. Marshall AJ, Du Q, Draves KE, Shikishima Y, HayGlass KT, Clark EA. FDC-SP, a novel secreted protein expressed by follicular dendritic cells. J Immunol. 2002;169(5):2381–9.

    Article  CAS  PubMed  Google Scholar 

  15. van den Brand M, van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica. 2013;98(7):1003–13.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kanellis G, Roncador G, Arribas A, et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia. 2009;23(10):1847–57.

    Article  CAS  PubMed  Google Scholar 

  17. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ogura G, Kikuti YY, Kikuchi T, Carreras J, Sato T, Nakamura N. MYD88 (L265P) mutation in malignant lymphoma using formalin-fixed paraffin-embedded section. J Clin Exp Hematop. 2013;53(2):175–7.

    Article  PubMed  Google Scholar 

  19. Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121(22):4504–11.

    Article  CAS  PubMed  Google Scholar 

  20. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–33.

    Article  CAS  PubMed  Google Scholar 

  21. Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013;140(3):387–94.

    Article  CAS  PubMed  Google Scholar 

  22. Falini B, Agostinelli C, Bigerna B, et al. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology. 2012;61(5):930–41.

    Article  PubMed  Google Scholar 

  23. Younes SF, Beck AH, Ohgami RS, et al. The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol. 2011;135(5):697–708.

    Article  CAS  PubMed  Google Scholar 

  24. Chapman-Fredricks J, Younes SF, Fan YS, Sandoval-Sus JD, Natkunam Y, Lossos IS. Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract. Appl Immunohistochem Mol Morphol. 2013;21(3):200–4.

    Article  CAS  PubMed  Google Scholar 

  25. Dyhdalo KS, Lanigan C, Tubbs RR, Cook JR. Immunoarchitectural patterns of germinal center antigens including LMO2 assist in the differential diagnosis of marginal zone lymphoma vs follicular lymphoma. Am J Clin Pathol. 2013;140(2):149–54.

    Article  PubMed  Google Scholar 

  26. Marafioti T, Copie-Bergman C, Calaminici M, et al. Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology. 2013;62(6):860–75.

    Article  PubMed  Google Scholar 

  27. Montes-Moreno S, Roncador G, Maestre L, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood. 2008;111(1):351–8.

    Article  CAS  PubMed  Google Scholar 

  28. Paterson MA, Hosking PS, Coughlin PB. Expression of the serpin centerin defines a germinal center phenotype in B-cell lymphomas. Am J Clin Pathol. 2008;130(1):117–26.

    Article  CAS  PubMed  Google Scholar 

  29. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zeng W, Fu K, Quintanilla-Fend L, Lim M, Ondrejka S, Hsi ED. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012;36(2):214–9.

    Article  PubMed  Google Scholar 

  31. Gradowski JF, Sargent RL, Craig FE, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression. Am J Clin Pathol. 2012;138(1):132–9.

    Article  PubMed  Google Scholar 

  32. Ferrando AA. SOX11 is a mantle cell lymphoma oncogene. Blood. 2013;121(12):2169–70.

    Article  CAS  PubMed  Google Scholar 

  33. Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2013;119(18):4215–23.

    Article  CAS  Google Scholar 

  34. Kondratiev S, Duraisamy S, Unitt CL, et al. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol. 2011;35(10):1531–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Tapia G, Lopez R, Muñoz-Mármol AM, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology. 2011;59(4):672–8.

    Article  PubMed  Google Scholar 

  36. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36(4):612–9.

    Article  PubMed  Google Scholar 

  37. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012;7(4):e33813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gupta M, Maurer MJ, Wellik LE, et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood. 2012;120(22):4400–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Gonin J, Larousserie F, Bastard C, et al. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS One. 2011;6(9):e24617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Bedewy AM, Elgammal MM, Bedewy MM, El-Maghraby SM. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma. Ann Hematol. 2013;92(10):1359–67.

    Article  CAS  PubMed  Google Scholar 

  41. Tang H, Wei Q, Ge J, et al. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma. Hum Pathol. 2013;44(10):2167–72.

    Article  CAS  PubMed  Google Scholar 

  42. Marafioti T, Paterson JC, Ballabio E, et al. The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica. 2010;95(3):432–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2011;35(1):76–83.

    Article  PubMed  Google Scholar 

  44. Mao Y, Zhang DW, Zhu H, et al. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). Diagn Pathol. 2012;7:178.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36(12):1796–800.

    Article  PubMed  Google Scholar 

  46. Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119(1):188–91.

    Article  CAS  PubMed  Google Scholar 

  47. Akarca AU, Shende VH, Ramsay AD, et al. BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol. 2013;162(6):848–51.

    Article  CAS  PubMed  Google Scholar 

  48. Dabbs DJ. Diagnostic immunohistochemistry. 3rd ed. Philadelphia: Churchill Livingstone Elsevier; 2010. p. 274, 308, 405.

    Google Scholar 

  49. Campo E, Ghia P, Montserrat E, Harris NL, Muller-Hermelink HK, Stein H and Swerdlow S.H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues Revised 4th ed. Lyon: International Agency for Research on Cancer, 2017, p. 216.

    Google Scholar 

  50. Campo E, Matutess E, Montserrat E, Harris NL, Stein H, Muller-Hermelink HK. B-cell prolymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 222.

    Google Scholar 

  51. Piris MA, Isaacson PG, Swerdlow SH, Thieblemont C, Pittaluga S, Rossi D, Harris NL. Splenic B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 223.

    Google Scholar 

  52. Foucar K, Falini B, Catovsky D, Stein H. Hairy cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 226.

    Google Scholar 

  53. Chen YH, Tallman MS, Goolsby C, Peterson L. Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol. 2006;125(5):251–9.

    Article  PubMed  Google Scholar 

  54. Piris M, Foucar K, Mollejo M, Matutes E, Campo E, Falini B, Swerdlow SH. Splenic B-cell lymphoma/leukaemia, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 229.

    Google Scholar 

  55. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood. 2008;111(4):2253–60.

    Article  CAS  PubMed  Google Scholar 

  56. Swerdlow SH, Cook JR, Sohani AR, Pileri SA, Harris NL, Jaffe ES, Stein H. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 232.

    Google Scholar 

  57. Cook JR, Swerdlow SH, Sohani AR, Pileri SA, Harris NL, Jaffe ES, Stein H. IgM monoclonal gammopathy of undetermined significance. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 236.

    Google Scholar 

  58. Cook JR, Harris NL, Issacson PG, Jaffe ES. Heavy chain disease. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 237.

    Google Scholar 

  59. McKenna RW, Kyle RA, Kuehl WM, Harris NL, Coupland RW, Fend F. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 241.

    Google Scholar 

  60. Cook JR, Isaacson PG, Chott A, Nakamura S, Muller-Hermelink HK, Harris NL, Swerdlow SH. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 259.

    Google Scholar 

  61. Campo E, Pileri SA, Jaffe ES, Nathwani BN, Stein H, Muller-Hermelink HK. Nodal marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 263.

    Google Scholar 

  62. Jaffe ES, Harris NL, Swerdlow SH, Ott G, Nathwani BN, de Jone D, Yoshino T, Spagnolo D, Gascoyne RD. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 266.

    Google Scholar 

  63. Jaffe ES, Harris NL, Siebert R. Paediatric-type follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 278.

    Google Scholar 

  64. Pittaluga S, Harris NL, Siebert R, Salaverria I. Large B-cell lymphoma with IRF4 rearrangement. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 280.

    Google Scholar 

  65. Willemze R, Swerdlow SH, Harris NL, Vergier B. Primary cutaneous follicular center lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 282.

    Google Scholar 

  66. Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 285.

    Google Scholar 

  67. Gascoyne RD, Campo E, Jaffe ES, Chan WC, Chang JKC, Rosenwald A, Sein H, Swerdlow SH. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 291.

    Google Scholar 

  68. Ott G, Delabie J, Gascoyne RD, Campo E, Sein H, Jaffe ES. T cell/histiocyte-rich large B cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 298.

    Google Scholar 

  69. Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 300.

    Google Scholar 

  70. Willemze R, Vergier B, Duncan LM. Primary cutaneous DLBCL, leg type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 303.

    Google Scholar 

  71. Nakamura S, Jaffe ES, Swerdlow SH. EBV positive diffuse large B-cell lymphoma, not otherwise specified (NOS). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 304.

    Google Scholar 

  72. Gaulard P, Swerdlow SH, Harris NL, Sundstrom C, Jaffe ES. EBV positive mucocutaneous ulcer. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 307.

    Google Scholar 

  73. Chan JKC, Aozasa K, Gaulard P. DLBCL associated with chronic inflammation. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 309.

    Google Scholar 

  74. Pittaluga S, Wilson WH, Jaffe ES. Lymphomatoid granulomatosis. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 312.

    Google Scholar 

  75. Gaulard P, Harris NL, Pileri SA, Stein H, Kovrigina AM, Jaffe ES, Moller P, Gascoyne RD. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 314.

    Google Scholar 

  76. Dorfman DM, Shahsafaei A, Alonso MA. Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers. Mod Pathol. 2012;25(12):1637–43.

    Article  CAS  PubMed  Google Scholar 

  77. Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 317.

    Google Scholar 

  78. Campo E, Gascoyne RD. ALK-positive large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 319.

    Google Scholar 

  79. Campo E, Stein H, Harris NL. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 321.

    Google Scholar 

  80. Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 323.

    Google Scholar 

  81. Said J, Isaacson PG, Campo E, Harris NL. HHV8-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 325.

    Google Scholar 

  82. Burbelo PD, Issa AT, Ching KH, et al. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. J Infect Dis. 2010;201(12):1919–22.

    Article  PubMed  Google Scholar 

  83. Leoncini L, Campo E, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 330.

    Google Scholar 

  84. Leoncini L, Campo E, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt-like lymphoma with 11q aberration. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 334.

    Google Scholar 

  85. Kluin PM, Harris NL, Stein H, Leoncini L, Campo E, Jaffe ES, Gascoyne RD, Swerdlow SH. High-grade B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 335.

    Google Scholar 

  86. Jaffe ES, Stein H, Swerdlow SH, Campo E, Pileri SA, Harris NL. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma, classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 342.

    Google Scholar 

  87. Matutes E, Catovsky D, Muller-Hermelink HK. T-cell prolymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 346.

    Google Scholar 

  88. Chan WC, Foucar K, Morice WG, Matutes E. T-cell large granular lymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 348.

    Google Scholar 

  89. Villamor N, Morice WG, Chan WC, Foucar K. Chronic lymphoproliferative disorders of NK cells. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 351.

    Google Scholar 

  90. Chan JKC, Jaffe ES, Ko YH. Aggressive NK-cell leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 353.

    Google Scholar 

  91. Quintanilla-Martines L, Ko YH, Kimura H, Jaffe ES. EBV-positive T-cell lymphoproliferative disorders of childhood. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 355.

    Google Scholar 

  92. Ohshima K, Jaffe ES, Yoshino T, Siebert R. Adult T-cell leukemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 363.

    Google Scholar 

  93. Chan JKC, Quintanilla-Martines L, Ferry JA. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 368.

    Google Scholar 

  94. Jaffe ES, Chott A, Ott G, Chan JKC, Tan SY, Stein H, Isaacson PG. Intestinal T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 372.

    Google Scholar 

  95. Gaulard P, Jaffe ES, Krenacs L, Macon WR. Hepatosplenic T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 381.

    Google Scholar 

  96. Jaffe ES, Gaulard P, Cerroni L. Subcutaneous panniculitis-like T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 383.

    Google Scholar 

  97. Cerroni L, Sander CA, Smoller BR, Willemze R, Sieber R. Mycosis fungoides. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 385.

    Google Scholar 

  98. Whittaker SJ, Cerroni L, Willemze R, Siebert R. Sezary syndrome. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 390.

    Google Scholar 

  99. Willemze R, Pauli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 392.

    Google Scholar 

  100. McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C. The differential diagnosis of CD8-positive (“type D”) lymphomatoid papulosis. J Cutan Pathol. 2014;41(2):88–100.

    Article  PubMed  Google Scholar 

  101. Bertolotti A, Pham-Ledard AL, Vergier B, Parrens M, Bedane C, Beylot-Barry M. Lymphomatoid papulosis type D: an aggressive histology for an indolent disease. Br J Dermatol. 2013;169(5):1157–9.

    Article  CAS  PubMed  Google Scholar 

  102. Andersen RM, Skaarup Larsen M, Svenstrup Poulsen T, Falensteen Lauritzen A, Skov L. Lymphomatoid papulosis type D or an aggressive epidermotropic CD8 cytotoxic T-cell lymphoma? Acta Derm Venereol. 2014;94:474–5. https://doi.org/10.2340/00015555-1750.

    Article  PubMed  Google Scholar 

  103. Cho-Vega JH, Vega F. CD30-negative lymphomatoid papulosis type D in an elderly man. Am J Dermatopathol. 2014;36(2):190–2.

    Article  PubMed  Google Scholar 

  104. Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology. 2015;67(4):425–41. https://doi.org/10.1111/his.12371.

    Article  PubMed  Google Scholar 

  105. Gaulard P, Berti E, Willemze R, Petrella T, Jaffe ES. Primary cutaneous peripheral T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 397.

    Google Scholar 

  106. Pilrei SA, Weisenburger DD, Song I, Nakamura S, Muller-Hermelink HK, Chan WC, Jaffe ES. Peripheral T-cell lymphoma, not otherwise specified (NOS). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 403.

    Google Scholar 

  107. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–9.

    Article  CAS  PubMed  Google Scholar 

  108. Dogan A, Gaulard P, Jaffe ES, Muller-Hermelink HK, Deleval L. Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 407.

    Google Scholar 

  109. Falini B, Lamant-Rochaix L, Campo E, Jaffe ES, Gsacoyne RD, Stein H, Muller-Hermelink HK, Kinney MC. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 413.

    Google Scholar 

  110. Feldman AL, Harris NL, Stein H, Campo E, Kinney MC, Jaffe ES, Falini B, Inghirami GG, Pileri SA. Anaplastic large cell lymphoma (ALCL), ALK-negative. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 418.

    Google Scholar 

  111. Feldman AL, Harris NL, Stein H, Campo E, Kinney MC, Jaffe ES, Falini B, Inghirami GG, Pileri SA. Breast implant-associated anaplastic large cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 421.

    Google Scholar 

  112. Stein H, Swerdlow SH, Gascoyne RD, Poppema S, Jaffe ES, Pileri SA. Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 431.

    Google Scholar 

  113. Stein H, Delsol G, Pileri SA, MacLennan KA, Poppema S, Guenova M, Gascoyne RD, Jaffe ES. Classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 435.

    Google Scholar 

  114. Van Krieken JH, Onciu M, Elenitoba-Johnson KSJ, Jaffe ES. Lymphoproliferative diseases associated with primary immune disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 444.

    Google Scholar 

  115. Said J, Cesarman E, Rosenwald A, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 449.

    Google Scholar 

  116. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 453.

    Google Scholar 

  117. Gaulard P, Swerdlow SH, Harris NL, Sundstrom C, Jaffe ES. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 462.

    Google Scholar 

  118. Weiss LM, Pileri SA, Chan JKC, Fletcher CDM. Histiocytic sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 468.

    Google Scholar 

  119. Weiss LM, Jaffe R, Facchetti F. Tumor derived from Langerhans cells. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 473.

    Google Scholar 

  120. Weiss LM, Chan JKC, Fletcher CDM. Indeterminate dendritic cell tumor. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 474.

    Google Scholar 

  121. Weiss LM, Chan JKC. Interdigitating dendritic cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 475.

    Google Scholar 

  122. Chan JKC, Pileri SA, Fletcher CDM, Weiss LM, Grogan TM. Follicular dendritic cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 476.

    Google Scholar 

  123. Weiss LM, Chan JKC, Fletcher CDM. Fibroblastic reticular cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 479.

    Google Scholar 

  124. Brousse N, Pileri SA, Haroche J, Dagna L, Jaffe R, Fletcher CDM, Jaffe ES, Harris NL. Disseminated juvenile xanthogranuloma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 480.

    Google Scholar 

  125. Brousse N, Pileri SA, Haroche J, Dagna L, Jaffe R, Fletcher CDM, Jaffe ES, Harris NL. Erdheim-Chester disease. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 481.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Geisinger Health System, Wilkes-Barre, PA, USA

    Xiaohong Mary Zhang

  2. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Yi Ding

Authors
  1. Xiaohong Mary Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaohong Mary Zhang .

Editor information

Editors and Affiliations

  1. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Fan Lin

  2. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Jeffrey W. Prichard

  3. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Haiyan Liu

  4. Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA

    Myra L. Wilkerson

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Geisinger Clinic

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhang, X.M., Ding, Y. (2022). Lymph Node. In: Lin, F., Prichard, J.W., Liu, H., Wilkerson, M.L. (eds) Handbook of Practical Immunohistochemistry. Springer, Cham. https://doi.org/10.1007/978-3-030-83328-2_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-83328-2_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-83327-5

  • Online ISBN: 978-3-030-83328-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation